|
1
|
Scadden DT: Cancer stem cells refined. Nat
Immunol. 5:701–703. 2004.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Visvader JE and Lindeman GJ: Cancer stem
cells: Current status and evolving complexities. Cell Stem Cell.
10:717–728. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Magee JA, Piskounova E and Morrison SJ:
Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer
Cell. 21:283–296. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chen D, Wu M, Li Y, Chang L, Yuan Q,
Ekimyan-Salvo M, Deng P, Yu B, Yu Y, Dong J, et al: Targeting BMI1+
cancer stem cells overcomes chemoresistance and inhibits metastases
in squamous cell carcinoma. Cell Stem Cell. 20:621–634.
2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
White RA, Neiman JM, Reddi A, Han G,
Birlea S, Mitra D, Dionne L, Fernandez P, Murao K, Bian L, et al:
Epithelial stem cell mutations that promote squamous cell carcinoma
metastasis. J Clin Invest. 123:4390–4404. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Meacham CE and Morrison SJ: Tumour
heterogeneity and cancer cell plasticity. Nature. 501:328–337.
2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li J, Condello S, Thomes-Pepin J, Ma X,
Xia Y, Hurley TD, Matei D and Cheng JX: Lipid desaturation is a
metabolic marker and therapeutic target of ovarian cancer stem
cells. Cell Stem Cell. 20:303–314, e305. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Codd AS, Kanaseki T, Torigo T and Tabi Z:
Cancer stem cells as targets for immunotherapy. Immunology.
153:304–314. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ohkoshi E and Umemura N: Induced
overexpression of CD44 associated with resistance to apoptosis on
DNA damage response in human head and neck squamous cell carcinoma
cells. Int J Oncol. 50:387–395. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Nanbu T, Umemura N, Ohkoshi E, Nanbu K,
Sakagami H and Shimada J: Combined SN-38 and gefitinib treatment
promotes CD44 degradation in head and neck squamous cell carcinoma
cells. Oncol Rep. 39:367–375. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pena-Solorzano D, Stark SA, Konig B,
Sierra CA and Ochoa-Puentes C: ABCG2/BCRP: Specific and nonspecific
modulators. Med Res Rev. 37:987–1050. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chen Z, Shi T, Zhang L, Zhu P, Deng M,
Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters
of the ATP binding cassette (ABC) family in multidrug resistance: A
review of the past decade. Cancer Lett. 370:153–164.
2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lu BC, Li J, Yu WF, Zhang GZ, Wang HM and
Ma HM: Elevated expression of Nrf2 mediates multidrug resistance in
CD133+ head and neck squamous cell carcinoma stem cells. Oncol
Lett. 12:4333–4338. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Guan GF, Zhang DJ, Zheng Y, Wen LJ, Yu DJ,
Lu YQ and Zhao Y: Significance of ATP-binding cassette transporter
proteins in multidrug resistance of head and neck squamous cell
carcinoma. Oncol Lett. 10:631–636. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hu J, Li J, Yue X, Wang J, Liu J, Sun L
and Kong D: Expression of the cancer stem cell markers ABCG2 and
OCT-4 in right-sided colon cancer predicts recurrence and poor
outcomes. Oncotarget. 8:28463–28470. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xiong B, Ma L, Hu X, Zhang C and Cheng Y:
Characterization of side population cells isolated from the colon
cancer cell line SW480. Int J Oncol. 45:1175–1183. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Posner MR, Hershock DM, Blajman CR,
Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM,
Cullen K, Ervin TJ, et al: Cisplatin and fluorouracil alone or with
docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715.
2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Bolstad BM, Irizarry RA, Astrand M and
Speed TP: A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics. 19:185–193. 2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Gentleman RC, Carey VJ, Bates DM, Bolstad
B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al:
Bioconductor: Open software development for computational biology
and bioinformatics. Genome Biol. 5(R80)2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Quackenbush J: Microarray data
normalization and transformation. Nat Genet. 32 Suppl:S496–S501.
2002.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Takeishi S and Nakayama KI: Role of Fbxw7
in the maintenance of normal stem cells and cancer-initiating
cells. Br J Cancer. 111:1054–1059. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Takeishi S, Matsumoto A, Onoyama I, Naka
K, Hirao A and Nakayama KI: Ablation of Fbxw7 eliminates
leukemia-initiating cells by preventing quiescence. Cancer Cell.
23:347–361. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Saito Y, Uchida N, Tanaka S, Suzuki N,
Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, et
al: Induction of cell cycle entry eliminates human leukemia stem
cells in a mouse model of AML. Nat Biotechnol. 28:275–280.
2010.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Kukal S, Guin D, Rawat C, Bora S, Mishra
MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S, et al:
Multidrug efflux transporter ABCG2: Expression and regulation. Cell
Mol Life Sci. 78:6887–6939. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Fletcher JI, Haber M, Henderson MJ and
Norris MD: ABC transporters in cancer: More than just drug efflux
pumps. Nat Rev Cancer. 10:147–156. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
27
|
Moniot B, Declosmenil F, Barrionuevo F,
Scherer G, Aritake K, Malki S, Marzi L, Cohen-Solal A, Georg I,
Klattig J, et al: The PGD2 pathway, independently of FGF9,
amplifies SOX9 activity in Sertoli cells during male sexual
differentiation. Development. 136:1813–1821. 2009.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chaffer CL, Dopheide B, Savagner P,
Thompson EW and Williams ED: Aberrant fibroblast growth factor
receptor signaling in bladder and other cancers. Differentiation.
75:831–842. 2007.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Giancotti FG: Mechanisms governing
metastatic dormancy and reactivation. Cell. 155:750–764.
2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Modok S, Mellor HR and Callaghan R:
Modulation of multidrug resistance efflux pump activity to overcome
chemoresistance in cancer. Curr Opin Pharmacol. 6:350–354.
2006.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kage K, Tsukahara S, Sugiyama T, Asada S,
Ishikawa E, Tsuruo T and Sugimoto Y: Dominant-negative inhibition
of breast cancer resistance protein as drug efflux pump through the
inhibition of S-S dependent homodimerization. Int J Cancer.
97:626–630. 2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Suresh R, Ali S, Ahmad A, Philip PA and
Sarkar FH: The role of cancer stem cells in recurrent and
drug-resistant lung cancer. Adv Exp Med Biol. 890:57–74.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Nieh S, Jao SW, Yang CY, Lin YS, Tseng YH,
Liu CL, Lee TY, Liu TY, Chu YH and Chen SF: Regulation of tumor
progression via the Snail-RKIP signaling pathway by nicotine
exposure in head and neck squamous cell carcinoma. Head Neck.
37:1712–1721. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang J, Wu Y, Gao W, Li F, Bo Y, Zhu M, Fu
R, Liu Q, Wen S and Wang B: Identification and characterization of
CD133+CD44+ cancer stem cells from human laryngeal squamous cell
carcinoma cell lines. J Cancer. 8:497–506. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lee Y, Shin JH, Longmire M, Wang H, Kohrt
HE, Chang HY and Sunwoo JB: CD44+ cells in head and neck squamous
cell carcinoma suppress T-cell-mediated immunity by selective
constitutive and inducible expression of PD-L1. Clin Cancer Res.
22:3571–3581. 2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wagner T, Wirth J, Meyer J, Zabel B, Held
M, Zimmer J, Pasantes J, Bricarelli FD, Keutel J, Hustert E, et al:
Autosomal sex reversal and campomelic dysplasia are caused by
mutations in and around the SRY-related gene SOX9. Cell.
79:1111–1120. 1994.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Tanaka J, Mabuchi Y, Hata K, Yasuhara R,
Takamatsu K, Kujiraoka S, Yukimori A, Takakura I, Sumimoto H,
Fukada T, et al: Sox9 regulates the luminal stem/progenitor cell
properties of salivary glands. Exp Cell Res.
382(111449)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Khorani K, Schwaerzler J, Burkart S, Kurth
I, Holzinger D, Flechtenmacher C, Plinkert PK, Zaoui K and Hess J:
Establishment of a plasticity-associated risk model based on a
SOX2- and SOX9-related gene set in head and neck squamous cell
carcinoma. Mol Cancer Res. 19:1676–1687. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Al-Zahrani KN, Abou-Hamad J, Pascoal J,
Labreche C, Garland B and Sabourin LA: AKT-mediated phosphorylation
of Sox9 induces Sox10 transcription in a murine model of
HER2-positive breast cancer. Breast Cancer Res.
23(55)2021.PubMed/NCBI View Article : Google Scholar
|
